Vortioxetine 20 mg/day

DRUG2 trials

Sponsors

H. Lundbeck A/S

Conditions

Depressive Disorder, Major

Phase 3

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

CompletedNCT02709746

H. Lundbeck A/SDepressive Disorder, Major

Start: 2016-05-31End: 2019-07-30Updated: 2020-08-19

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

CompletedNCT02709655

H. Lundbeck A/SDepressive Disorder, Major

Start: 2016-05-18End: 2022-01-21Updated: 2022-09-22

Related Papers

Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study.

2024-11-22

Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies

European Child & Adolescent Psychiatry2024-09-061 citations

Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.

2022-01-1318 citations